ERBB2 and breast carcinoma: According to a previous study integrating machine learning technology into determining risk factors in breast cancer survivors, the number of metastatic lymph nodes, breast cancer grading, presence of lymphovascular invasion, type of estrogen therapy before breast cancer, age of the patient at diagnosis, trastuzumab therapy, human epidermal growth factor receptor 2 (HER2), and taxane-based chemotherapy have been characterized as the most important risk factors for BCRL development [8].